<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1975694886019755&amp;ev=PageView&amp;noscript=1">

Remington-Davis launches dedicated COVID-19 research unit in Ohio

By Chris Newmarker | July 8, 2020

Clinical research outfit Remington-Davis recently announced that it has launched a dedicated 3,000 ft2 space in Columbus, Ohio for COVID-19 clinical trials.

The space includes six private overnight rooms, patient lounge, dedicated laboratory, oxygen therapy and more. Participants must be 18 or older with COVID-19 symptoms and have a laboratory-confirmed SARS-CoV2 infection.

“We were not able to see our regular research patients and COVID patients in the same space, so we opened a new location dedicated to COVID studies,” said Remington-Davis director Hamish Baird.

Clinical trials have started for REGN-COV2, Regeneron’s anti-viral antibody cocktail for the treating and preventing COVID-19.

As Featured in:

image (1)